pAAVS1-Puro-DNR 载体 (V012309)

我们所展示的质粒图谱主要是从文献和开放数据库中收集而来,主要是为了方便研究工作,其中一小部分质粒进行了质量控制,可供科学家使用。

所有的产品都严格仅供科学研究使用,不能应用于临床试验,包括人体摄入、注射或外用的药理学用途。

确保质粒的关键元件正确,但是我们并不能保证实验结果。页面展示的图谱序列为理论序列,可能与测序结果不一致,请自行比对后确定是否满足要求。(如果测过序,本页面一般会提供下载)

开放数据库中的大多数载体序列都没有被完全测序。如果实际序列与参考序列的相似度超过99%,则将其视为正确。

由于科学研究是在探索未知,具有很大的不确定性,在任何情况下,我们都不承担超出质粒本身的额外经济损失或责任。

载体名称:
pAAVS1-Puro-DNR
载体抗性:
Ampicillin
载体长度:
7507 bp
载体类型:
CRISPR Plasmids
复制子:
ori
载体来源:
OriGene
拷贝数:
High copy number
启动子:
mPGK

pAAVS1-Puro-DNR 载体载体图谱

pAAVS1-Puro-DNR7507 bp3006009001200150018002100240027003000330036003900420045004800510054005700600063006600690072007500lac operatorlac promoterCAP binding siteoriAmpRAmpR promoterf1 oriM13 fwdHA-LloxPPGK poly(A) signalPuroRPGK promoterCMV enhancerCMV promoterT7 promoterMCSMycFLAGM13 revhGH poly(A) signalHA-R

质粒操作方法

1. 发货形式:质粒干粉(常温运输,存于-20度,请务必先转化提质粒后使用)

2. 收到质粒干粉后请先5000rpm离心1min,再加入20μl ddH2O溶解质粒;(质粒复测的浓度有时候与标称值差距较大,这可能是因为冻干质粒在管中的位置、复溶效率、测量偏差以及管壁的吸附导致,因此建议先转化提质粒后再使用)

3. 取1支100μl 感受态于冰上解冻10min,加入2μl质粒,再冰浴30min后,42℃热激60s,不要搅动,再冰浴2min;

4. 加入900μl无抗的LB液体培养基,180rpm震荡37℃培养45min (30℃培养1-1.5小时);

5. 6000rpm离心5min,仅留100μl上清液重悬细菌沉淀,并涂布至目标质粒抗性的LB平板上;

6. 将平板倒置37℃培养14h,如果要求是30℃则培养20h; (菌落过多则将质粒稀释后再转化;没有菌落则加入10μl质粒转化;建议不要直接转表达感受态, 要先转克隆感受态,重提质粒后再导入表达感受态);

7. 挑取单菌落至LB液体培养基中,加入对应抗生素,220rpm震荡培养14h,根据实验需要和质粒提取试剂盒说明书提取质粒。

pAAVS1-Puro-DNR 载体载体序列

LOCUS       pAAVS1-Puro-DNR.        7507 bp DNA     circular SYN 01-JAN-1980
DEFINITION  Mammalian donor vector for transgene integration at the AAVS1 locus 
            in the human genome. Use together with pCas-Guide-AAVS1.
ACCESSION   .
VERSION     .
KEYWORDS    pAAVS1-Puro-DNR
SOURCE      synthetic DNA construct
  ORGANISM  synthetic DNA construct
REFERENCE   1  (bases 1 to 7507)
  AUTHORS   OriGene
  TITLE     Direct Submission
REFERENCE   2  (bases 1 to 7507)
  AUTHORS   .
  TITLE     Direct Submission
COMMENT     SGRef: number: 1; type: "Journal Article"
FEATURES             Location/Qualifiers
     source          1..7507
                     /mol_type="other DNA"
                     /organism="synthetic DNA construct"
     protein_bind    complement(119..135)
                     /label=lac operator
                     /note="The lac repressor binds to the lac operator to
                     inhibit transcription in E. coli. This inhibition can be 
                     relieved by adding lactose or 
                     isopropyl-beta-D-thiogalactopyranoside (IPTG)."
     promoter        complement(143..173)
                     /label=lac promoter
                     /note="promoter for the E. coli lac operon"
     protein_bind    complement(188..209)
                     /label=CAP binding site
                     /note="CAP binding activates transcription in the presence
                     of cAMP."
     rep_origin      complement(497..1085)
                     /direction=LEFT
                     /label=ori
                     /note="high-copy-number ColE1/pMB1/pBR322/pUC origin of 
                     replication"
     CDS             complement(1259..2116)
                     /label=AmpR
                     /note="beta-lactamase"
     promoter        complement(2117..2221)
                     /label=AmpR promoter
     rep_origin      complement(2503..2958)
                     /direction=LEFT
                     /label=f1 ori
                     /note="f1 bacteriophage origin of replication; arrow
                     indicates direction of (+) strand synthesis"
     primer_bind     3171..3187
                     /label=M13 fwd
                     /note="common sequencing primer, one of multiple similar 
                     variants"
     misc_feature    3278..3779
                     /label=HA-L
                     /note="left homology arm from the adeno-associated virus 
                     integration site (AAVS1) within intron 1 of the human 
                     PPP1R12C gene"
     protein_bind    complement(3792..3824)
                     /label=loxP
                     /note="Cre-mediated recombination occurs in the 8-bp core 
                     sequence (ATGTATGC) (Shaw et al., 2021)."
     polyA_signal    complement(3851..4304)
                     /label=PGK poly(A) signal
                     /note="mouse phosphoglycerate kinase 1 polyadenylation
                     signal"
     CDS             complement(4384..4980)
                     /label=PuroR
                     /note="puromycin N-acetyltransferase"
     promoter        complement(5020..5519)
                     /label=PGK promoter
                     /note="mouse phosphoglycerate kinase 1 promoter"
     enhancer        5637..5940
                     /label=CMV enhancer
                     /note="human cytomegalovirus immediate early enhancer"
     promoter        5941..6144
                     /label=CMV promoter
                     /note="human cytomegalovirus (CMV) immediate early
                     promoter"
     promoter        6170..6188
                     /label=T7 promoter
                     /note="promoter for bacteriophage T7 RNA polymerase"
     misc_feature    6197..6300
                     /label=MCS
                     /note="MCS"
                     /note="multiple cloning site"
     CDS             6303..6332
                     /label=Myc
                     /note="Myc (human c-Myc proto-oncogene) epitope tag"
     CDS             6351..6374
                     /label=FLAG
                     /note="FLAG(R) epitope tag, followed by an enterokinase
                     cleavage site"
     primer_bind     complement(6394..6410)
                     /label=M13 rev
                     /note="common sequencing primer, one of multiple similar 
                     variants"
     polyA_signal    6421..6897
                     /label=hGH poly(A) signal
                     /note="human growth hormone polyadenylation signal"
     misc_feature    6972..7501
                     /label=HA-R
                     /note="right homology arm from the adeno-associated virus 
                     integration site (AAVS1) within intron 1 of the human 
                     PPP1R12C gene"